Search

everythinglearnresearchcommunity

for

Search:↓

Lower TNF-α levels in PRP may predict better treatment outcomes for bladder conditions.

Lgr5+ stem cells do not cause skin tumors.

The type of tumor suppressor affects the form of skin cancer from hair follicle stem cells.

TNF-inhibitor induced alopecia can be treated effectively with different therapies.

IL-15 and TNF-α levels are higher in alopecia areata patients, especially in alopecia totalis.

The type of tumor suppressor gene lost affects the behavior of skin cancer.

Oral pulse steroids reduce TNF-α levels, improving alopecia areata.

DNA virus-induced tumors have consistent isozyme profiles, unlike other tumor types.

Tumor proteins can both promote and suppress cancer, depending on the situation.

Stopping TNFα inhibitors can help children regrow hair lost due to the medication.

Recognizing rare tumor combinations is crucial for accurate diagnosis and treatment.

The technique effectively repairs skin after tumor removal, maintaining appearance and function without complications.

Early diagnosis and treatment are crucial to prevent permanent hair loss from TNFα inhibitors in scalp psoriasis.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

Birth control pills change the activity of certain inflammation and blood clotting genes in women with PCOS.

Some drugs used to treat immune conditions may cause different types of hair loss.

A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.

Some canine hair follicle tumors contain amyloid deposits, with a protein called CK5 involved in their formation.

External factors can cause skin cancer cells that usually don't spread to grow and form tumors in mice.

Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.

Tumor immunotherapy can cause hair loss by disrupting hair follicle immunity.

Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.

Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.

TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.

Consider TFI in facial hypopigmentation diagnoses and confirm with a biopsy.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

An automated system can predict death risk in thin melanoma by analyzing immune cells.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Loss of the p53 gene alone causes tumors, and losing both p53 and Rb genes speeds up aggressive skin cancer.